Ibogaine: the research, the cardiac risks and the legal picture

Ibogaine is a plant-derived psychedelic that has produced striking early results for PTSD, depression and traumatic brain injury in small studies, including a Stanford study of 30 special operations veterans. It is also one of the most dangerous psychedelics for the heart: it prolongs the QT interval and has been linked to arrhythmias and sudden cardiac deaths. In the US it is a Schedule I drug, and the only legitimate path forward is controlled clinical research, which Texas is now funding with $50 million.

That combination, dramatic early signals plus serious cardiac risk, is why ibogaine has moved from the fringe into conversations among veterans, policymakers and, increasingly, founders who have heard about it at a dinner or on a podcast. This piece lays out what the research actually shows and why the risks are not a footnote.

This is an educational overview. It is not a recommendation to use ibogaine, and nothing here describes how to obtain, dose or take it.

What is ibogaine, and why is everyone talking about it?

Ibogaine is a psychoactive alkaloid derived from a plant. Its reputation in addiction circles goes back decades, based on reports that a single experience could blunt opioid withdrawal and cravings. What changed recently is the research profile.

In January 2024, a Stanford team led by Nolan Williams published results in Nature Medicine on veterans with traumatic brain injury (TBI). The results were large enough that Williams told Stanford Medicine: "No other drug has ever been able to alleviate the functional and neuropsychiatric symptoms of traumatic brain injury. The results are dramatic."

In June 2025, Texas passed what advocates called "the largest state-funded psychedelic research initiative in history," aimed squarely at getting ibogaine through FDA trials. Former Texas Governor Rick Perry became one of its loudest champions.

Then there is the other half of the story, which advocates tend to rush past. As Scientific American put it in April 2026, ibogaine "has caused sudden cardiac death, including in people using the drug to treat mental health conditions."

What did the Stanford veterans study find?

The Stanford study enrolled 30 special operations veterans with histories of TBI, the kind of repeated blast and impact exposure that often comes with long careers in combat roles. According to Stanford Medicine, the veterans received oral ibogaine together with magnesium "to help prevent heart complications that have been associated with ibogaine," and they were under medical monitoring throughout.

One month after treatment, the average reductions in symptoms were large.

Disability scores on a standard World Health Organization scale fell from an average of 30.2, in the mild to moderate range, to 5.1, which corresponds to no disability. Stanford reported "no serious side effects of ibogaine and no instances of the heart problems that have occasionally been linked to ibogaine." A follow-up paper in Nature Mental Health in July 2025 expanded on the findings.

Why the headline numbers need a caveat

The study had no control group. Every participant knew they were receiving ibogaine, many had sought it out, and all went through an intense, highly structured experience with preparation and support. That design cannot separate the drug's effect from expectation, the setting, the attention, or the natural tendency of extreme symptom scores to drift back toward average.

Thirty people is also a small sample, drawn from a very specific group: highly motivated veterans who passed medical screening. That screening matters, because it excludes the people most likely to be harmed.

Sandeep Nayak of Johns Hopkins offered a fair summary to Scientific American: "The ibogaine research that has been done does not fully match the excessively rosy picture touted by advocates."

None of that means the results are wrong. It means they are a strong reason to run proper randomized trials, which is exactly where the field is heading.

Why is ibogaine so risky for the heart?

This is the central issue, and it is not speculative.

Your heart beats because of carefully timed electrical currents. After each beat, heart muscle cells have to "reset" electrically before the next one. On an electrocardiogram, the QT interval reflects how long that reset takes. When it gets too long, the heart becomes vulnerable to a chaotic rhythm called torsade de pointes, which can degenerate into cardiac arrest.

A 2015 review in Molecules by Xaver Koenig and Karlheinz Hilber, titled "The anti-addiction drug ibogaine and the heart: a delicate relation," lays out the mechanism. Ibogaine and its main metabolite, noribogaine, block hERG potassium channels, which carry one of the key currents that resets the heart. The authors conclude that ibogaine causes arrhythmias through "(1) blockade of repolarizing hERG potassium channels; (2) retardation of the repolarization phase of the ventricular AP; and (3) concomitant prolongation of the QT interval."

Three details from that review should give anyone pause:

• The deaths. "Between the years 1990 and 2008 a total of 19 fatalities temporally associated with the ingestion of ibogaine were reported," with more reported since.
• The duration. QT prolongation after ibogaine "typically lasts for more than 24 hours" and has persisted longer than a week in some cases. The risk does not end when the experience does.
• The magnitude. In eight cases documented since 2008, reported corrected QT intervals ranged from 480 milliseconds to more than 700.

What a case report looks like

A 2016 case report and literature review in Therapeutic Advances in Psychopharmacology describes a patient who went into cardiac arrest less than eight hours after taking ibogaine. His corrected QT interval later peaked at 588 milliseconds. He had no known heart disease and no family history of cardiac problems. The authors note that other case reports describe patients found in torsade de pointes after ibogaine use.

The same review cites an earlier analysis in which 15 of the 19 deaths were associated with detoxification, meaning people using ibogaine to come off opioids or other drugs. That is the population most drawn to it and, often, the population with the most complicated medical picture.

What the magnesium in the Stanford study was for

The Stanford protocol paired ibogaine with magnesium specifically to protect the heart, and screened participants carefully. No cardiac problems occurred in that group of 30. That is encouraging for the idea that risk can be managed in a controlled medical setting. It is not evidence that ibogaine is safe outside one, and 30 screened participants is far too few to rule out a rare fatal event.

What is ibogaine's legal status?

Federal law. Ibogaine has been a Schedule I drug in the US since 1970, according to Stanford Medicine. Schedule I is the most restrictive category, reserved for substances the federal government considers to have high abuse potential and no accepted medical use. Possession is illegal. Research can happen only under specific federal approvals.

Texas. On June 11, 2025, Governor Greg Abbott signed SB 2308, which, as KUT News reported, commits $50 million in state funds to FDA-approved clinical trials of ibogaine for opioid use disorder and other conditions, including PTSD and traumatic brain injury. Private investors, including drug developers, must match the state's money, and if ibogaine wins FDA approval, Texas will receive a share of the revenue.

It is worth being precise about what this does. It funds trials. It does not legalize ibogaine in Texas or anywhere else, and it does not create a legal way for individuals to use it. Reporting on the law noted that ibogaine's cardiac risks require pre-screening, monitoring and clinical preparation, which is exactly what a trial provides.

Outside the US. Much of the current human experience with ibogaine, including the Stanford study, comes from medically monitored settings outside the US. Regulation and medical standards vary enormously from place to place. The cardiac risk does not.

What the evidence says, and what it doesn't

Established: Ibogaine prolongs the QT interval through hERG channel blockade. Deaths and cardiac arrests temporally associated with its use have been documented in the medical literature, and QT prolongation can last more than a day.

Early and promising: A small, uncontrolled Stanford study found large reductions in PTSD, depression, anxiety and disability in veterans with TBI, with no serious adverse events under medical monitoring and magnesium co-administration.

Unknown: Whether those results hold up in randomized, controlled trials. How durable the effects are. How rare serious cardiac events are under the best medical protocols. Who is safe to treat and who is not.

Not supported: The idea that ibogaine is safe because it is natural, or that a single session is a reliable fix for addiction, trauma or burnout.

If you are struggling with substance use, trauma symptoms or the after-effects of a head injury, talk to a physician or licensed clinician. If you are considering any psychedelic, a medical evaluation of your heart and medications is the minimum, and legitimate clinical trials, which are registered and screened, are the only responsible route for a Schedule I drug.

What a founder can actually do with this information

Most founders reading this are not veterans with blast injuries. They are curious, often exhausted, sometimes looking for a reset after a brutal stretch or a disorienting exit. A few practical takeaways:

Treat dinner-party stories as anecdotes. You will hear about someone's transformative experience. You will not hear from the people whose hearts stopped. Survivorship bias is strong in psychedelic storytelling.

Know your own cardiac baseline. If you have never had an ECG, have palpitations, take medications that affect heart rhythm, or have a family history of sudden cardiac death, those are facts your physician should know before you consider anything that stresses the heart.

Follow the trials, not the hype. The Texas program and academic groups like Stanford's are where real answers will come from over the next several years. Randomized results will tell you far more than any testimonial.

Address the underlying need. The pull toward a single dramatic intervention usually says something about what you are carrying: an identity gap after an exit, chronic stress, or grief that has not had anywhere to go. Our pieces on the identity gap after an exit and on meditation beyond stress relief look at those needs directly.

Doing the deeper work without the cardiac risk

The appeal of ibogaine is real: the promise that one experience could reach what years of grinding have not. Some of what people are looking for, a different relationship to their own mind and a nervous system that is not stuck in threat mode, can be trained deliberately, safely and legally.

That is the work we do at Cinder: private 1:1 meditation coaching for founders and executives, focused on stress regulation, attention and the harder transitions of a career. It will not make headlines, and it does not come with a cardiac monitor.

Apply for private coaching

Sources

• Psychoactive drug ibogaine effectively treats traumatic brain injury in special ops military vets, Stanford Medicine, 2024 (updated 2025)
• The anti-addiction drug ibogaine and the heart: a delicate relation, Molecules (via PMC), 2015
• Ibogaine-associated cardiac arrest and death: case report and review of the literature, Therapeutic Advances in Psychopharmacology, 2016
• Texas will invest $50 million into psychedelic research under new law, KUT News, 2025
• RFK, Jr., says ibogaine holds unprecedented promise for treating depression. Here's what the science says, Scientific American, 2026